12 Information Technology Stocks Moving In Tuesday’s After-Market Session

Gainers Peraso (NASDAQ:PRSO) stock increased by 8.6% to $0.19 during Tuesday’s after-market session. The market value of their…

Gainers

  • Peraso (NASDAQ:PRSO) stock increased by 8.6% to $0.19 during Tuesday’s after-market session. The market value of their outstanding shares is at $5.2 million.
  • Auddia (NASDAQ:AUUD) stock rose 8.41% to $0.32. The market value of their outstanding shares is at $6.2 million.
  • Oblong (NASDAQ:OBLG) stock moved upwards by 7.1% to $0.46. Trading volume for this security closed at 3.3 million, accounting for 2379.3% of its average full-day volume over the last 100 days. The company’s market cap stands at $1.8 million.
  • SatixFy Communications (AMEX:SATX) stock increased by 6.33% to $0.6. The company’s market cap stands at $48.1 million.
  • Movella Holdings (NASDAQ:MVLA) shares moved upwards by 6.04% to $0.52. The company’s market cap stands at $26.4 million.
  • Aeva Technologies (NYSE:AEVA) shares rose 4.99% to $0.7. The company’s market cap stands at $156.6 million.

Losers

  • A10 Networks (NYSE:ATEN) stock decreased by 13.7% to $13.1 during Tuesday’s after-market session. The market value of their outstanding shares is at $970.8 million.
  • MicroAlgo (NASDAQ:MLGO) shares decreased by 11.59% to $1.9. The company’s market cap stands at $83.3 million.
  • Mawson Infra Gr (NASDAQ:MIGI) shares declined by 6.13% to $0.61. The company’s market cap stands at $10.0 million.
  • Datasea (NASDAQ:DTSS) shares fell 5.8% to $0.2. The company’s market cap stands at $6.3 million. As per the news, the Q4 earnings report came out 4 days ago.
  • Data Storage (NASDAQ:DTST) shares decreased by 4.88% to $3.12. The market value of their outstanding shares is at $21.3 million.
  • GSE Systems (NASDAQ:GVP) shares decreased by 4.35% to $0.2. The company’s market cap stands at $4.9 million.
    See Also: www.benzinga.com/money/tech-stocks/

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Newly Listed Lenz Therapeutics’ Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study

LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary endpoints without compromising distance visual acuity. LNZ100's safety profile remains favorable, paving the way for its lead candidacy, poised for mid-2024 NDA submission.

LENZ